Charles Peterfy
About
In The Last Decade
Charles Peterfy
173 papers receiving 12.4k citations
Hit Papers
Peers
Comparison fields: 5 of 153
- Rheumatology 10.4k
- Surgery 4.1k
- Biomedical Engineering 2.0k
- Hematology 2.0k
- Orthopedics and Sports Medicine 1.9k
Countries citing papers authored by Charles Peterfy
This map shows the geographic impact of Charles Peterfy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Peterfy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Peterfy more than expected).
Fields of papers citing papers by Charles Peterfy
This network shows the impact of papers produced by Charles Peterfy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Peterfy. The network helps show where Charles Peterfy may publish in the future.
Co-authorship network of co-authors of Charles Peterfy
This figure shows the co-authorship network connecting the top 25 collaborators of Charles Peterfy. A scholar is included among the top collaborators of Charles Peterfy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Peterfy. Charles Peterfy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 130 | |
| 3 | 5 | |
| 4 | 132 | |
| 5 | 15 | |
| 6 | 23 | |
| 7 | Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis | 2 |
| 8 | Rituximab (RTX) plus Methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-score) | 16 |
| 9 | 67 | |
| 10 | 79 | |
| 11 | Reduced Radiographic Progression in Patients with Early Rheumatoid Arthritis (RA) Treated with Abatacept plus Methotrexate Compared to Methotrexate Alone: 24 Month Outcomes | 2 |
| 12 | Disease Remission is Achieved Within Two Years In Over Half of Methotrexate Naive Patients with Early Erosive Rheumatoid Arthritis (RA) Treated with Abatacept Plus MTX: Results from The AGREE Trial | 5 |
| 13 | 148 | |
| 14 | The efficacy and safety of abatacept in methotrexate-naive patients with early erosive rheumatoid arthritis and poor prognostic factors | 25 |
| 15 | The osteoarthritis initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee breakdown → | 556 |
| 16 | 312 | |
| 17 | 74 | |
| 18 | Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis. | 60 |
| 19 | Knee joint cartilage topography, thickness and contact areas: Validation of measurements from MRI | 3 |
| 20 | 146 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.